NervGen Pharma Corp.
NGENF · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $240,339 | $246,635 | $203,324 | $219,676 |
| - Cash | $11,364 | $15,675 | $14,471 | $17,267 |
| + Debt | $33 | $58 | $82 | $106 |
| Enterprise Value | $229,008 | $231,018 | $188,935 | $202,515 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$6,157 | -$6,455 | -$6,021 | -$6,790 |
| % Margin | – | – | – | – |
| Net Income | -$4,156 | -$9,104 | -$3,948 | -$8,609 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.06 | -0.13 | -0.056 | -0.12 |
| % Growth | 53.8% | -132.6% | 53.4% | – |
| Operating Cash Flow | -$5,318 | -$3,665 | -$4,119 | -$3,660 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$5,318 | -$3,665 | -$4,119 | -$3,660 |